Upadacitinib for the management of severe alopecia areata in adolescent patients: a single-centre retrospective study
- PMID: 39096263
- DOI: 10.1093/ced/llae309
Upadacitinib for the management of severe alopecia areata in adolescent patients: a single-centre retrospective study
Conflict of interest statement
Conflicts of interest M.N. has acted as speaker, consultant and advisory board member for Abbvie, Eli Lilly, Leo Pharma, Novartis and Sanofi. C.P. has acted as investigator, speaker, consultant and advisory board member for AbbVie, Amgen, Eli Lilly, Leo Pharma, Novartis, Pfizer, Pierre Fabre and Sanofi. M.C. has acted as speaker for Eli Lilly. The remaining authors declare no conflict of interest.
LinkOut - more resources
Full Text Sources
